Affordable Access

Download Read

Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients

Oxford Univ. Press
  • 610 Medizin
  • 615 Pharmazie


Objectives: To assess the pharmacokinetics of moxifloxacin in morbidly obese patients. Methods: Twelve morbidly obese patients (2 male/10 female, age 25–61 years, weight 98–166 kg, body mass index 43.0–58.2 kg/m2) scheduled for gastric bypass surgery were treated with 400 mg of moxifloxacin orally once daily for 3 days and with 400 mg of moxifloxacin intravenously on day 4 (day of surgery). Pharmacokinetic analysis was performed on day 1 and day 4. Specimens of small intestine, greater omentum and subcutaneous adipose tissue were collected intraoperatively 1.8–3.7 h after moxifloxacin infusion. Moxifloxacin concentrations were determined by HPLC. Results: The plasma pharmacokinetics (mean ± SD) was comparable to historical data in normal-weight subjects. Oral bioavailability was 79.6% ± 11.5%. After intravenous administration, plasma clearance was 9.6 ± 2.0 L/h, volume of distribution was 165 ± 30 L and area under the curve was 43.7 ± 11.8 mg·h/L. Linear regression analysis showed the volume of distribution to be better correlated with ideal body weight, lean body weight, fat-free mass or height (R2 = 0.60–0.67, P = 0.001–0.003) than with total body weight (R2 = 0.46, P = 0.015). Whereas mean tissue concentrations in small intestine (6.99 ± 2.34 mg/kg) were twice the concomitant plasma concentrations, the concentrations in greater omentum (0.801 ± 0.168 mg/kg) or subcutaneous fat (0.638 ± 0.180 mg/kg) were only one-quarter of those. Conclusions: The pharmacokinetics of moxifloxacin is not significantly affected by morbid obesity. No dose adjustment seems to be necessary in this particular population.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times
Downloaded <100 times